Castillo Aleman Yandy Marx, Villegas Valverde Carlos Agustin, Ventura Carmenate Yendry, Abdel Hadi Loubna, Rivero Jimenez Rene Antonio, Rezgui Rachid, Alagha Shahd Hani, Shamat Shadi, Bencomo Hernandez Antonio Alfonso
Abu Dhabi Stem Cells Center (ADSCC) Abu Dhabi, United Arab Emirates (UAE).
New York University Abu Dhabi, United Arab Emirates (UAE).
Am J Stem Cells. 2021 Oct 15;10(4):68-78. eCollection 2021.
Drug delivery by nebulization has become a crucial strategy for treating different respiratory and lung diseases. Emerging evidence implicates stem cell therapy as a promising tool in treating such conditions, not only by alleviating the related symptoms but by improving the prognosis. However, delivery of human peripheral blood-derived stem cells (hPBSCs) to the respiratory airways remains an innovative approach yet to be realized. This study is an analytic, translational, and research to assess the viability and morphological changes of identified cell populations in hPBSCs cocktail derived from COVID-19 patients.
Peripheral blood (PB) samples were obtained from patients enrolled in the SENTAD-COVID Study (ClinicalTrials.gov Reference: NCT04473170). hPBSCs cocktails (n=15) were provided by the Cells Processing Laboratory of Abu Dhabi Stem Cells Center, and were nebulized by three different methods of nebulization: compressor (jet), ultrasonic, and mesh. Our results reported that nucleated CD45 cell count was significantly lower after the three nebulization methods, but nucleated CD45 cells show a significant decrease only after mesh nebulization. Mesh-nebulized samples had a significant reduction in viability of both CD45 and CD45 cells.
This study provides evidence that stem cells derived from PB of COVID-19 patients can be nebulized without substantial loss of cell viability, cell count, and morphological changes using the compressor nebulization. Therefore, we recommend compressor nebulizers as the preferable procedure for hPBSCs delivery to the respiratory airways in further clinical settings.
雾化给药已成为治疗不同呼吸道和肺部疾病的关键策略。新出现的证据表明，干细胞疗法不仅可以缓解相关症状，还能改善预后，是治疗此类疾病的一种有前景的工具。然而，将人外周血来源的干细胞（hPBSCs）递送至呼吸道仍是一种尚未实现的创新方法。本研究是一项分析性、转化性研究，旨在评估COVID-19患者来源的hPBSCs混合液中已鉴定细胞群的活力和形态变化。
从参与SENTAD-COVID研究（ClinicalTrials.gov标识符：NCT04473170）的患者中获取外周血（PB）样本。hPBSCs混合液（n = 15）由阿布扎比干细胞中心的细胞处理实验室提供，并通过三种不同的雾化方法进行雾化：压缩空气（喷射）雾化、超声雾化和网状雾化。我们的结果显示，三种雾化方法后有核CD45细胞计数均显著降低，但只有在网状雾化后有核CD45细胞才出现显著减少。网状雾化样本中CD45细胞和CD45细胞的活力均显著降低。
本研究提供的证据表明，使用压缩空气雾化可以使COVID-19患者外周血来源的干细胞雾化，而不会导致细胞活力、细胞计数和形态发生实质性损失。因此，我们建议在进一步的临床应用中，将压缩空气雾化器作为将hPBSCs递送至呼吸道的首选方法。
